<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DONEPEZIL HYDROCHLORIDE <img border="0" src="../images/pr.gif"/></span><br/>(don-e'pe-zil)<br/><span class="topboxtradename">Aricept, </span><span class="topboxtradename">Aricept ODT<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">cholinergic (parasympathomimetic) agent</span>; <span class="classification">cholinesterase inhibitor</span>; <span class="classification">cholinergic, central acting</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg tablets and orally disintegrating tablets</p>
<h1><a name="action">Actions</a></h1>
<p>In early stages of Alzheimer's disease, pathologic changes in neurons result in deficiency of acetylcholine.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Aricept, a cholesterase inhibitor, presumably elevates acetylcholine concentration in the cerebral cortex by slowing degradation
         of acetylcholine released by remaining intact neurons.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Mild to moderate dementia of Alzheimer's type.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to donepezil or tracine; pregnancy (category C), lactation; children; GI bleeding, jaundice.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Anesthesia, sick sinus rhythm, AV block, bradycardia, cardiac arrhythmias, cardiac disease, hypotension; hyperthyroidism,
         history of ulcers, abnormal liver function; patients with asthma or obstructive pulmonary disease, history of seizures, seizures,
         urinary tract obstruction, intestinal obstruction; diarrhea, emesis, GI disease, renal failure, renal impairment, surgery.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Alzheimer's Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 510 mg h.s.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give at h.s. just prior to going to bed.</li>
<li>Increase dosage to 10 mg <small>ONLY</small> after 46 wk of therapy with the 5-mg dose.
         </li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> <span class="speceff-common">Headache,</span> fatigue. <span class="typehead">CNS:</span> <span class="speceff-common">Insomnia,</span> dizziness, depression, tremor, irritability, vertigo, ataxia. <span class="typehead">CV:</span> Syncope, hypertension, atrial fibrillation, hot flashes, hypotension. <span class="typehead">GI:</span> <span class="speceff-common">Nausea, diarrhea, vomiting, muscle cramps, anorexia,</span> GI bleeding, bloating, fecal incontinence, epigastric pain. <span class="typehead">Respiratory:</span> Dyspnea. <span class="typehead">Skin:</span> Pruritus, sweating, urticaria. <span class="typehead">Other:</span> Ecchymoses, muscle cramps, dehydration, blurred vision, urinary incontinence, nocturia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Ketoconazole,</b> <b>quinidine</b> may inhibit donepezil metabolism; <b>carbamazepine,</b> <b>dexamethasone,</b> <b>phenobarbital,</b> <b>phenytoin,</b> <b>rifampin</b> may increase donepezil elimination; donepezil may interfere with the action of <span class="classification">anticholinergic agents</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract. <span class="typehead">Peak plasma concentration:</span> 34 h. <span class="typehead">Distribution:</span> 96% protein bound. <span class="typehead">Metabolism:</span> Metabolized in the liver by CYP2D6 and CYP3A4 to at least 2 active metabolites. <span class="typehead">Elimination:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> 70 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor therapeutic effectiveness: Improvement as noted on the Alzheimer's Disease Assessment Scale.</li>
<li>Monitor closely for S&amp;S of GI ulceration and bleeding, especially with concurrent use of <small>NSAIDS</small>.
         </li>
<li>Monitor carefully patients with a history of asthma or obstructive pulmonary disease.</li>
<li>Monitor cardiovascular status; drug may have vagotonic effect on the heart, causing bradycardia, especially in presence of
            conduction abnormalities.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Exercise caution. Fainting episodes related to slowing the heart rate may occur.</li>
<li>Report immediately to physician any S&amp;S of GI ulceration or bleeding (e.g., "coffee-grounds" emesis, tarry stools,
            epigastric pain).
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>